Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 115Urinary Bladder Neoplasms 56Carcinoma, Non-Small-Cell Lung 53Cholangiocarcinoma 33Biliary Tract Neoplasms 32Neoplasm Metastasis 30Ovarian Neoplasms 29Lymphoma, Large B-Cell, Diffuse 27Breast Neoplasms 25Neoplasms 24Lung Neoplasms 24Carcinoma, Transitional Cell 23Triple Negative Breast Neoplasms 22Nasopharyngeal Carcinoma 21Colorectal Neoplasms 20Non-Muscle Invasive Bladder Neoplasms 19Recurrence 17Fallopian Tube Neoplasms 16Gallbladder Neoplasms 15Sarcoma 13Bile Duct Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Hodgkin Disease 10Lymphoma 9Adenocarcinoma 9Uterine Cervical Neoplasms 8Stomach Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Nasopharyngeal Neoplasms 6

Interventions

atezolizumab 2pembrolizumab 1liposomal doxorubicin 1Tumor Necrosis Factor-alpha 1Gemcitabine 1Cell Count 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoviridae Infections × Gemcitabine × 1 year × Clear all
NCT02705196 2026-02-24

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Lokon Pharma AB

Phase 1/2 Completed
51 enrolled
Gastrointestinal

Adenoviridae Infections, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡